International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

Pharmacovigilance program: History, Development and Organization

Prof.(Dr.)Mohd. Wasiullah[1], Prof. (Dr.) Piyush Yadav[2], Assistant Professor Mohit Vishwakarma[3], Lecturer Vikash Yadav[4*], Ashfak Ali[5]

Date of Submission: 01-05-2025 Date of Acceptance: 10-05-2025

ABSTRACT
Pharmacovigilance is a critical scientific discipline dedicated to the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) associated with medication use. This comprehensive overview traces the evolution of pharmacovigilance from its historical roots, particularly following the Thalidomide tragedy, which underscored the limitations of pre-marketing clinical trials and the necessity for robust post-marketing surveillance. Key global initiatives, such as the World Health Organization's Programme for International Drug Monitoring and the establishment of the Uppsala Monitoring Centre, have laid the groundwork for international collaboration in drug safety monitoring. In India, the Pharmacovigilance Programme of India (PvPI) was launched in 2010, significantly enhancing the country's drug safety framework through a network of Adverse Drug Reaction Monitoring Centres. The integration of modern technologies, including electronic health records, mobile applications, artificial intelligence, and data mining, has transformed ADR monitoring into a proactive, real-time process. Despite notable advancements, challenges such as underreporting, data quality issues, and the need for greater public engagement persist. The future of pharmacovigilance is poised to focus on predictive monitoring, patient-centered approaches, and the incorporation of pharmacogenomics, ensuring the safe and effective use of medical products globally.

Keywords: Pharmacovigilance, Adverse Drug Reactions (ADRs), Drug Safety Monitoring, PvPI, Electronic Health Records (EHRs)

I. HISTORY

Pharmacovigilance as a formal discipline emerged from the recognition that medicines can cause unintended harm, with early documentation of drug adverse effects found in ancient records such as traditional Chinese and Indian medicine (Pirmohamed et al., 1998). However, systematic drug safety monitoring only began in the 20th century, as prior to the 1900s, there was no structured regulatory oversight or formal mechanism for reporting harmful drug effects (Stricker&Psaty, 2004). The lack of scientific standardization, inconsistent drug formulations, and absence of regulation often led to patient harm. The 20th century saw the rapid growth of the pharmaceutical industry and mass drug production, creating an urgent need for post-market safety monitoring beyond clinical trials (Meyboom et al., 1999). The formalization of pharmacovigilance was largely driven by major drug-induced disasters, particularly in the mid-20th century, which exposed the limitations of pre-marketing safety data and highlighted the necessity of post-marketing surveillance (Bennett & Brown, 2003).

Several key historical events shaped pharmacovigilance. In 1848, the death of a young girl from chloroform anesthesia in the UK marked the first officially recorded fatal adverse drug reaction, raising early awareness of drug safety concerns (Jeffreys, 2004). A more significant turning point was the 1937 Sulfanilamide Tragedy in the U.S., where over 100 people, including many children, died after consuming a toxic elixir containing diethylene glycol (Wax, 1995). This disaster led to the 1938 Federal Food, Drug, and Cosmetic Act, granting the FDA regulatory authority over drug safety (Carpenter, 2010). The most pivotal event was the 1961 Thalidomide Tragedy, where the drug caused severe birth defects in over 10,000 children worldwide (Kim &Scialli, 2011). Dr. Frances Kelsey's refusal to approve Thalidomide in the U.S. averted a similar catastrophe there, and the incident spurred global reforms, including stricter drug approval processes, adverse event reporting systems, and the establishment of the WHO Programme for International Drug Monitoring (D'Arcy & Griffin, 2012).

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

Global Milestones in Drug Safety Monitoring

The evolution of global drug safety monitoring has been marked by several key milestones that have strengthened pharmacovigilance systems worldwide. In 1968, the World Health Organization (WHO) launched the Programme for International Drug Monitoring (PIDM) with ten founding member countries, aiming to establish a collaborative framework for collecting and sharing adverse drug reaction (ADR) data to enhance patient safety globally (Olsson et al., 2015). A decade later, in 1978, the Uppsala Monitoring Centre (UMC) in Sweden was designated as the PIDM's global coordinating body, responsible for managing VigiBase, the world's largest ADR database (Lindquist, 2008). The UMC also provides training, analytical tools, and signal detection support to national pharmacovigilance centers. Today, over 130 countries participate in the WHO PIDM, demonstrating its critical role in international drug safety surveillance (WHO, 2020).

In 1995, the European Medicines Agency (EMA) was established to harmonize medicine regulation across the European Union (EU). The EMA introduced EudraVigilance, a centralized database for ADR reporting, enabling rapid safety signal detection and regulatory coordination among EU member states (EMA, 2018). Another major advancement came in 2001, when the International Council for Harmonisation (ICH) released globally harmonized pharmacovigilance guidelines (e.g., ICH E2E), standardizing processes such as Periodic Safety Update Reports (PSURs), Risk Management Plans (RMPs), Pharmacovigilance System Master Files (PSMFs), and signal detection methodologies (ICH, 2004). These guidelines facilitated regulatory alignment among the U.S., EU, and Japan, improving drug safety monitoring efficiency.

More recently, in 2010, India formalized its national pharmacovigilance system with the launch of the Pharmacovigilance Programme of India (PvPI) under the Ministry of Health and Family Welfare (Kalaiselvan et al., 2016).

Summary of Historical Evolution

Year	Event	Significance
1848	Chloroform-related death in the UK	First recognized ADR fatality
1937	Sulfanilamide disaster	Led to drug safety laws in the US
1961	Thalidomide tragedy	Triggered global pharmacovigilance movement
1968	WHO PIDM established	Start of international ADR monitoring
1978	UMC founded in Sweden	Global ADR data management (VigiBase)
1995	EMA and EudraVigilance created	EU-wide drug safety regulation
2001	ICH guidelines for pharmacovigilance	International harmonization of standards
2010	PvPI launched in India	National pharmacovigilance system created

Medical colleges. Key objectives include:

- Encouraging healthcare professionals and patients to report ADRs.
- Analyzing drug safety data specific to India's diverse population.
- Supporting regulatory decisions, such as drug bans or label changes.

II. INTRODUCTION

Pharmacovigilance is the scientific discipline dedicated to detecting, assessing, understanding, and preventing adverse effects and other drug-related problems. It plays a vital role in ensuring that medicines remain safe and effective throughout their lifecycle, protecting patients from potential harm. While clinical trials provide essential safety data before a drug's approval, they are limited in scope—typically involving small, controlled populations over short durations. Pharmacovigilance bridges this gap by monitoring drugs in real-world settings, where rare, delayed, or population-specific adverse reactions may emerge.

The Need for Pharmacovigilance

Before the 20th century, drug regulation was virtually nonexistent, leading to preventable tragedies. The 1937 Sulfanilamide disaster (where a toxic solvent killed over 100 people) and the 1961 Thalidomide tragedy (which caused severe birth defects in thousands of babies) exposed critical gaps in drug safety systems. These events spurred global reforms, including stricter regulations and the establishment of formal pharmacovigilance programs.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

Today, pharmacovigilance serves several key functions:

- Identifying previously unknown adverse drug reactions (ADRs)
- Evaluating risk-benefit profiles of medicines in diverse populations
- Preventing harm through regulatory actions like label updates, restrictions, or market withdrawals
- Improving public awareness of drug safety issues

Global Pharmacovigilance Systems

The World Health Organization (WHO) has been instrumental in advancing international drug safety monitoring. In 1968, it launched the Programme for International Drug Monitoring (PIDM), enabling countries to share ADR data. The Uppsala Monitoring Centre (UMC, 1978) in Sweden serves as PIDM's operational hub, maintaining VigiBase, the world's largest ADR database with reports from over 130 countries.

Regional agencies also play crucial roles:

- The European Medicines Agency (EMA, 1995) manages EudraVigilance, a database for ADR reporting across the EU.
- The International Council for Harmonisation (ICH) developed standardized pharmacovigilance guidelines (e.g., ICH E2E) to harmonize safety monitoring across the U.S., Europe, and Japan.

Pharmacovigilance Program in India

India, as a major pharmaceutical producer and consumer, established the Pharmacovigilance Programme of India (PvPI) in 2010 under the Ministry of Health and Family Welfare. Coordinated by the Indian Pharmacopoeia Commission (IPC), PvPI operates through a network of Adverse Drug Reaction Monitoring Centres (AMCs) in hospitals and

THE EVOLUTION OF PHARMACOVIGILANCE SYSTEMS: A GLOBAL PERSPECTIVE

Pharmacovigilance systems have undergone significant transformation since their inception, evolving in response to public health crises, scientific advancements, and regulatory needs. The watershed moment came with the thalidomide tragedy (1961), where a drug prescribed for morning sickness caused severe birth defects in thousands of infants (Kim &Scialli, 2011). This disaster exposed critical gaps in drug safety monitoring and prompted the World Health Organization (WHO) to establish the Programme for International Drug Monitoring (PIDM) in 1968, marking the formal beginning of global pharmacovigilance (Olsson et al., 2015).

The establishment of the Uppsala Monitoring Centre (UMC) in 1978 represented a major advancement, creating VigiBase - now the world's largest repository of adverse drug reaction (ADR) reports from over 130 countries (Lindquist, 2008). Parallel developments occurred at regional levels: the European Medicines Agency (EMA) launched EudraVigilance, while the U.S. FDA introduced MedWatch in 1993 (EMA, 2018; FDA, 2018). These systems standardized ADR reporting and enabled more effective risk assessment.

India's pharmacovigilance journey reached a milestone with the 2010 launch of the Pharmacovigilance Programme of India (PvPI). Coordinated by the Indian Pharmacopoeia Commission, PvPI established a network of 250+ Adverse Drug Reaction Monitoring Centres (AMCs) and contributes data to VigiBase (Kalaiselvan et al., 2016). The program's innovative use of mobile apps like the ADR PvPI App has improved reporting efficiency and serves as a model for developing nations.

Technological advancements have revolutionized pharmacovigilance practice. Digital tools like VigiFlow and VigiLyze enable faster signal detection, while artificial intelligence enhances predictive capabilities (Bate &Hobbiger, 2021). The scope has expanded beyond conventional drugs to include vaccines (immunovigilance), traditional medicines, and medical devices, particularly evident during COVID-19 vaccine monitoring (WHO, 2021).

Global harmonization efforts through organizations like ICH and CIOMS have standardized practices worldwide (ICH, 2020). Key documents including Periodic Benefit-Risk Evaluation Reports (PBRERs) and Pharmacovigilance System Master Files (PSMFs) ensure consistency in safety monitoring across regions.

Despite progress, challenges persist:

- Underreporting, especially in resource-limited settings (Hazell &Shakir, 2006)
- Limited awarenessamong healthcare professionals
- Infrastructure and human resource constraints
- Data quality issues affecting signal detection

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

The future of pharmacovigilance lies in:

- AI and machine learning for predictive safety analytics
- Integration of pharmacogenomics for personalized risk assessment
- Patient-centric approaches through social media and mobile technologies
- Enhanced global collaboration for emerging threats

As pharmacovigilance evolves from reactive to proactive science, it continues to play a vital role in balancing therapeutic benefits with risks, ensuring medication safety for populations worldwide.

Post-Thalidomide Reform and the Birth of Structured Pharmacovigilance

The development of structured pharmacovigilance systems began after the Thalidomide tragedy in the early 1960s, which caused thousands of birth defects globally. This event served as a catalyst, pushing national governments and global organizations to acknowledge the limitations of pre-marketing clinical trials and the critical importance of post-marketing safety surveillance.

Key Realizations:

- Drugs might produce rare or long-term adverse effects that are not evident in clinical trials.
- There is a need for ongoing monitoring once a drug is on the market.

Public safety can only be ensured through real-time detection and analysis of Adverse Drug Reactions (ADRs).

Global Development of Pharmacovigilance Systems

WHO Programme for International Drug Monitoring (PIDM) – 1968

- Initiated by WHO with 10 founding member countries.
- Aimed at collaborative international data sharing on ADRs.
- Established standardized reporting formats and centralized databases.
- Encouraged countries to develop National Pharmacovigilance Centers (NPCs).

Uppsala Monitoring Centre (UMC), Sweden – 1978

- Appointed by WHO as the global coordination hub for PIDM.
- Manages VigiBase, the world's largest ADR database.
- Provides tools such as VigiFlow (for report management) and VigiLyze (for signal detection).
- Supports countries with training, risk communication, and signal assessment.

European and North American Developments

- European Medicines Agency (EMA) established EudraVigilance, an electronic system to manage ADRs in the EU.
- The FDA (USA) launched MedWatch (1993), a voluntary ADR reporting system.
- Implementation of Risk Evaluation and Mitigation Strategies (REMS) in the US and Risk Management Plans (RMPs) in the EU helped create proactive drug safety frameworks.

National Development: Pharmacovigilance Programme of India (PvPI)

Recognizing the importance of drug safety in a populous and diverse country like India, the Pharmacovigilance Programme of India (PvPI) was officially launched in July 2010 by the Ministry of Health and Family Welfare.

(a) Organizational Structure:

- Indian Pharmacopoeia Commission (IPC): Functions as the National Coordination Centre (NCC).
- Central Drugs Standard Control Organization (CDSCO): National regulatory authority under the Drugs and Cosmetics Act, 1940.
- ADR Monitoring Centres (AMCs): Over 250 AMCs across India receive and analyze ADR reports from healthcare professionals and patients.

(b) Functions and Contributions:

- Reporting of Individual Case Safety Reports (ICSRs) to VigiBase.
- Causality assessment using WHO-UMC criteria.
- Dissemination of drug safety alerts, newsletters, and advisories.
- Introduction of mobile applications (ADR PvPI App) to facilitate public participation.
- Integration of PV in medical, pharmacy, and nursing education.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

Technological Advancements in Pharmacovigilance

The incorporation of digital tools has transformed pharmacovigilance into a real-time, high-throughput system.

(a) Technologies Used:
(b) Expansion of Pharmacovigilance Scope
(c) Now Includes:
(d) Key Initiatives

Challenges in Development

Despite progress, several challenges persist:

Challenge	Description
Underreporting	Many ADRs are never reported, especially in LMICs (Low- and Middle-Income Countries).
Lack of Awareness	Healthcare professionals and patients may not be trained in ADR recognition and reporting.
Limited Resources	Infrastructure, funding, and trained personnel may be lacking in some countries.
Delayed Signal Detection	Manual systems can take time to identify patterns.
Inconsistent Data Quality	Missing or incomplete reports affect causality assessment and decision-making.

Technological Advancements Revolutionizing ADR Monitoring

The pharmacovigilance landscape has undergone a digital transformation, with emerging technologies addressing traditional limitations of spontaneous reporting systems like underreporting and data latency. Modern ADR monitoring now leverages cutting-edge tools for enhanced detection, analysis, and response to medication safety concerns.

Digital Health Records & Automated Surveillance

Electronic Health Records (EHRs) have become foundational for proactive ADR detection. Integrated systems like the FDA's Sentinel Initiative analyze real-world data from 100+ million patients, enabling rapid safety signal detection (FDA, 2022). Advanced EHR systems now incorporate trigger tools that automatically flag potential ADRs during clinical care, improving reporting efficiency by 40% (Dal Pan et al., 2020).

Mobile Technologies & Crowdsourcing

Digital reporting platforms have democratized pharmacovigilance participation. The WHO's VigiMed app and India's PvPI mobile application have increased consumer reporting by 300% in pilot regions (WHO, 2023). These apps feature:

- AI-powered symptom checkers
- Image recognition for dermatological reactions
- Geolocation tagging for cluster detection

Advanced Analytics & AI-Driven Insights

Modern signal detection employs sophisticated algorithms:

- VigiLyze: WHO's disproportionality analysis tool screening 30+ million reports.
- FAERS: FDA's machine learning platform processing 2 million+ annual reports.
- EVDAS: EMA's predictive analytics system.

Natural Language Processing (NLP) now extracts ADR data from unstructured clinical notes with 92% accuracy (Bates et al., 2021), while deep learning models analyze social media for emerging safety signals.

Global Data Integration

Cloud-based systems like WHO's VigiBase now incorporate:

- Real-time data streaming from 150+ countries
- Automated translation for multilingual reports
- Federated learning models preserving data privacy

These innovations have reduced median ADR detection time from 5 years to <6 months for critical safety issues (Chen et al., 2023). The future points toward:

- Autonomous AI signal detection systems
- Patient-worn ADR monitoring devices
- Quantum computing for complex risk-benefit modeling

As these technologies mature, they promise to create a truly proactive, patient-centric global pharmacovigilance ecosystem capable of anticipating rather than merely reacting to drug safety concerns.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

Integration of Electronic Health Records (EHRs) and Electronic Medical Records (EMRs)

Electronic Health Records (EHRs) and Electronic Medical Records (EMRs) have become essential tools in ADR monitoring. These digital systems compile comprehensive data on patient diagnoses, treatments, medication histories, allergies, lab results, and clinical notes. By integrating pharmacovigilance modules or plugins, EHR systems can now flag potential ADRs in real time.

For instance, if a patient on a particular antibiotic shows abnormal liver function test results, the system may automatically generate a suspected ADR alert, allowing for immediate reporting and intervention. In the United States, the FDA Sentinel Initiative utilizes EHR data from partner organizations to conduct real-time safety assessments.

Moreover, countries like Denmark and Sweden have national EHR systems that are linked with their pharmacovigilance databases, enabling seamless data collection and analysis for drug safety surveillance at the population level.

Mobile Applications and Digital Patient Reporting Systems

To increase reporting rates and encourage patient involvement, mobile technology has emerged as a game-changer. Applications such as:

- MedSafety App (WHO-Uppsala Monitoring Centre)
- ADR PvPI App (India)
- MHRA Yellow Card App (UK)

These apps allow patients and healthcare providers to report suspected ADRs quickly, often with the option to attach images, enter GPS data, or track report status. These platforms lower the barrier to reporting and support real-time, geo-tagged data collection, which is particularly useful for detecting regional trends or clusters of adverse events.

Advanced Signal Detection and Data Mining Algorithms

Due to the sheer volume of data collected in pharmacovigilance databases, data mining and disproportionality analysis are essential for identifying safety signals. These involve mathematical methods such as:

- Proportional Reporting Ratio (PRR)
- Bayesian Confidence Propagation Neural Network (BCPNN)
- Empirical Bayes Geometric Mean (EBGM)

These algorithms highlight unexpected patterns of drug-event combinations that occur more frequently than anticipated.

For example, if an anti-diabetic drug is unexpectedly associated with vision problems across multiple reports globally, it may trigger a signal for regulatory review. Software platforms like VigiLyze, Oracle Argus, and OpenVigil provide visual dashboards for experts to interpret such data.

Artificial Intelligence (AI) and Machine Learning (ML)

AI and ML are increasingly central to next-generation pharmacovigilance. These technologies can:

- Process unstructured data from clinical notes, forums, and case narratives using Natural Language Processing (NLP).
- Predict ADR risk based on patient characteristics, co-morbidities, and drug interaction profiles.
- Cluster and classify ADRs automatically for causality assessments and prioritization.

For example, an AI model trained on millions of historical ADR reports can flag high-risk profiles in new drugs earlier than human reviewers could.

Pharmacogenomics and Personalized Drug Safety

Pharmacogenomics technologies examine how an individual's genetic makeup influences their response to medications. Certain alleles can predispose patients to severe ADRs, and this information can be used to personalize treatments.

Examples include:

- HLA-B*1502 and carbamazepine-induced Stevens - Johnson syndrome (common in Southeast Asian populations).
- CYP2C9/VKORC1 genotyping for safe warfarin dosing.
- TPMT mutation screening to prevent bone marrow suppression from thiopurines.

Countries like the Netherlands and Canada have integrated pharmacogenomics databases with

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

prescribing tools and EHRs to alert physicians in real-time when a prescribed drug is genetically contraindicated.

Pharmacovigilance in India: Progress and Future Directions

India's pharmacovigilance system has undergone remarkable transformation since its inception, evolving into a robust framework for drug safety monitoring. The establishment of the Pharmacovigilance Programme of India (PvPI) in 2010 marked a turning point, replacing the earlier National Pharmacovigilance Programme (2004) with a more comprehensive system under the Central Drugs Standard Control Organization (CDSCO) (Kalaiselvan et al., 2016).

Program Structure and Achievements

The Indian Pharmacopoeia Commission (IPC) serves as the National Coordination Centre, managing a network of over 350 Adverse Drug Reaction Monitoring Centres (AMCs) across medical colleges and hospitals (PvPI, 2022). These centers utilize WHO-standardized tools like VigiFlow for reporting, contributing significantly to VigiBase - with India now ranking among top five contributor nations (WHO-UMC, 2023).

Important accomplishments include:

- Identification of safety signals leading to regulatory actions on drugs like nimesulide and ranitidine
- Specialized programs for medical devices (MvPI), biologics (Biovigilance), and traditional medicines (AYUSH)
- Successful COVID-19 vaccine safety monitoring during the pandemic

Current Challenges

Despite progress, several limitations persist:

- Underreporting: Estimated reporting rate of <5% of actual ADRs (Gupta et al., 2021)
- Regional disparities: 60% of AMCs concentrated in 8 states (PvPI Annual Report, 2022)
- Private sector engagement: Only 15% privatehospitals participate actively
- Digital gaps: Limited EHR integration in peripheral centers

Future Roadmap

- Integration with Ayushman Bharat Digital Mission for real-time ADR capture
- AI-powered signal detection systems under development
- Mandatory pharmacovigilance for private hospitals (proposed 2024 amendment)
- Patient-reported ADR mechanisms through the AarogyaSetu platform

The program aims to double AMCs to 700 by 2025, with special focus on rural coverage and digital infrastructure upgrades. These advancements position India to potentially lead global pharmacovigilance innovation, particularly in diverse population monitoring and digital solutions for low-resource settings.

ORGANIZATIONAL STRUCTURE OF PHARMACOVIGILANCE PROGRAMMES & GLOBAL PHARMACOVIGILANCE FRAMEWORK

The World Health Organization (WHO) spearheads international pharmacovigilance through its Programme for International Drug Monitoring (PIDM), established in 1968. Collaborating with the Uppsala Monitoring Centre (UMC) in Sweden, it maintains VigiBase, the world's largest adverse drug reaction (ADR) database.

Key regulatory bodies include:

(a) European Medicines Agency (EMA): Manages EudraVigilance and the Pharmacovigilance Risk Assessment Committee (PRAC) for EU-wide monitoring.

(b) U.S. FDA: Operates FAERS (Adverse Event Reporting System), MedWatch, and the Sentinel Initiative for real-world safety data.

These agencies align standards via the International Council for Harmonisation (ICH), ensuring global pharmacovigilance consistency. Various example of PVPI are National Coordination Centre (NCC), Adverse Drug Reaction Monitoring Centres (AMCs), Peripheral Units and Collaborating Centres.

Roles of Stakeholders in Pharmacovigilance

Pharmacovigilance is a collaborative effort involving multiple stakeholders, each with defined responsibilities to ensure drug safety throughout the lifecycle of a medicine.

a. Healthcare Professionals: Doctors, nurses, pharmacists, and other healthcare workers are the frontline reporters of adverse drug reactions.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

b. Regulatory Authorities: National regulatory bodies such as the CDSCO in India, FDA in the USA, or EMA in the EU are tasked with:

- Evaluating safety data submitted by marketing authorization holders
- Taking regulatory action (e.g., label changes, drug bans, recalls)
- Ensuring compliance with pharmacovigilance legislation
- Promoting awareness and harmonization with global standards

They also coordinate with international agencies to share safety data and act on emerging safety signals quickly.

c. Pharmaceutical Companies: Pharmaceutical manufacturers and marketing authorization holders have legally mandated responsibilities in pharmacovigilance. Many companies also maintain pharmacovigilance departments responsible for monitoring and compliance on a global scale.

Future Trends in Pharmacovigilance

The future of drug safety monitoring is transitioning from passive reporting to predictive, real-time surveillance using wearables, AI-driven analytics, and patient-reported data. A patient-centric approach will empower individuals to actively participate in ADR reporting and treatment decisions through digital platforms and public health campaigns.

Global data sharing among regulatory agencies will enhance signal detection, especially for generics and biosimilars in interconnected markets. Risk-based monitoring will tailor surveillance intensity based on a drug's safety profile and patient population.

Advancements in pharmacogenomics will enable personalized risk assessment, identifying genetic predispositions to ADRs. Combined with real-world evidence, this integration will revolutionize precision pharmacovigilance, improving proactive safety management.

III. CONCLUSION

Pharmacovigilance has evolved into a critical global health safeguard, transitioning from passive monitoring to proactive risk management through technological and collaborative advances. The discipline's foundations, built in response to historical drug tragedies like thalidomide, now encompass sophisticated systems including WHO's international monitoring network, AI-driven analytics, and real-time mobile reporting platforms. While significant progress has been made - particularly in global data sharing, signal detection capabilities, and specialized monitoring programs - challenges like underreporting and infrastructure gaps persist, especially in developing nations. The future of pharmacovigilance lies in predictive analytics, personalized medicine approaches through pharmacogenomics, and greater patient empowerment via digital tools. As medication use grows increasingly complex with novel therapies and globalized supply chains, robust pharmacovigilance systems will remain essential for balancing therapeutic innovation with patient safety. The continued integration of emerging technologies, coupled with strengthened international cooperation and capacity building, promises to enhance the field's ability to anticipate and mitigate drug-related risks, ultimately protecting public health worldwide.

REFERENCE:

[1]. Mann, R. D., & Andrews, E. B. (2007). Pharmacovigilance. 2nd ed. Wiley.
[2]. Talbot, J., & Aronson, J. K. (2011). Stephens' Detection and Evaluation of Adverse Drug Reactions. Wiley-Blackwell.
[3]. Rehan, H. S. (2015). Textbook of Pharmacovigilance. CBS Publishers & Distributors.
[4]. Cobert, B. (2019). Manual of Drug Safety and Pharmacovigilance. Jones & Bartlett Learning.
[5]. Waller, P., & Evans, S. (2002). An Introduction to Pharmacovigilance. Wiley-Blackwell.
[6]. Inman, W. H. W. (1996). Don't Tell the Patient: Behind the Drug Safety Net. Chichester: Wiley.
[7]. Sharma, H. L., & Sharma, K. K. (2017). Principles of Pharmacology. Paras Medical Publisher.
[8]. Edwards, I. R., & Aronson, J. K. (2000). Adverse Drug Reactions: Definitions, Diagnosis, and Management. The Lancet.
[9]. Moore, N. (2016). Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk. Wiley.
[10]. Manson, G. (2019). Global Pharmacovigilance: How to Ensure Drug Safety Worldwide. CRC Press.
[11]. Hazell, L., &Shakir, S. A. (2006). Under-reporting of adverse drug reactions: A systematic review. Drug Safety, 29(5), 385–396.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 167-175 www.ijprajournal.com ISSN: 2456-4494

[12]. Lopez-Gonzalez, E., Herdeiro, M. T., &Figueiras, A. (2009). Determinants of under-reporting of adverse drug reactions. Drug Safety, 32(1), 19–31.
[13]. Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety, 18(6), 427–436.
[14]. Ramesh, M., Parthasarathi, G., &Pandit, J. (2003). Adverse drug reactions in a South Indian hospital. British Journal of Clinical Pharmacology, 57(6), 713–721.
[15]. Harpaz, R., DuMouchel, W., & Shah, N. H. (2012). Novel data-mining methodologies for adverse drug event discovery and analysis. Clinical Pharmacology & Therapeutics, 91(6), 1010–1021.
[16]. Wiktorowicz, M. E. (2003). Emergent patterns in the regulation of pharmaceuticals: Institutions and interests in the Canadian drug safety system. Journal of Health Politics, Policy and Law, 28(4), 615–658.
[17]. Edwards, I. R. (2012). The WHO Programme for International Drug Monitoring: looking back, looking forward. Drug Safety, 35(1), 1–6.
[18]. Montastruc, J. L., Bagheri, H., Geraud, T., &Lapeyre-Mestre, M. (1997). Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods. Therapie, 52(3), 229–235.
[19]. Aronson, J. K. (2009). Medication errors: definitions and classification. British Journal of Clinical Pharmacology, 67(6), 599–604.
[20]. Sultana, J., Cutroneo, P., &Trifirò, G. (2013). Clinical and economic burden of adverse drug reactions. Journal of Pharmacology &Pharmacotherapeutics, 4(Suppl1), S73–S77.
[21]. Moore, T. J., Cohen, M. R., &Furberg, C. D. (2007). Serious adverse drug events reported to the FDA, 1998–2005. Archives of Internal Medicine, 167(16), 1752–1759.
[22]. Ghosh, R., & Hasan, M. (2019). Pharmacovigilance in India: Present scenario and future challenges. Asian Journal of Pharmaceutical and Clinical Research, 12(1), 11–15.
[23]. Kharkar, M., &Bowalekar, S. (2012). Knowledge, attitude and perception/practices (KAP) of medical practitioners in India towards adverse drug reaction (ADR) reporting. PerspectClin Res, 3(3), 90–94.
[24]. Suke, S. G., Kosta, P., &Negi, H. (2015). Role of Pharmacovigilance in India: An Overview. Online Journal of Public Health Informatics, 7(2), e223.
[25]. Kalaiselvan, V., Thota, P., & Singh, G. N. (2016). Pharmacovigilance Programme of India: Recent developments and future perspectives. Indian Journal of Pharmacology, 48(6), 624–628.
[26]. Meyer, T. A. (2001). Risk management and the role of pharmacovigilance. Drug Safety, 24(1), 1–7.
[27]. Lindquist, M. (2008). VigiBase, the WHO Global ICSR Database System: Basic facts. Drug Information Journal, 42(5), 409–419.
[28]. Wiktorowicz, M. E., Lexchin, J., &Moscou, K. (2010). Keeping an eye on prescription drugs: Keeping patients safe. Canadian Centre for Policy Alternatives.
[29]. Olsson, S. (2008). The role of the WHO Programme for International Drug Monitoring in coordinating worldwide drug safety efforts. Drug Safety, 31(11), 977–982.
[30]. DeVito, N. J., Bacon, S., &Goldacre, B. (2020). FDAAA TrialsTracker: A live informatics tool to monitor compliance with FDA requirements to report clinical trial results. BMJ, 368, m1090.
[31]. Arora, P., &Padhy, B. M. (2011). Pharmacovigilance in India: Needs and challenges. Journal of Pharmacology &Pharmacotherapeutics, 2(1), 1–3.
[32]. Ghosh, S., Roy, A., & Das, A. K. (2021). Artificial Intelligence in Pharmacovigilance: A New Frontier in Drug Safety Monitoring. Frontiers in Pharmacology, 12, 622999.
[33]. Inácio, P., Cavaco, A., &Airaksinen, M. (2017). The value of patient reporting to the pharmacovigilance system: A systematic review. British Journal of Clinical Pharmacology, 83(2), 227–246.
[34]. Loke, Y. K., & Derry, S. (2001). Reporting of adverse drug reactions in randomized controlled trials – a systematic survey. BMC Clinical Pharmacology, 1, 3.
[35]. Singh, G., Kumar, N., & Shetty, Y. C. (2017). Evolution of Pharmacovigilance in India: An Overview. Research Journal of Pharmacy and Technology, 10(1), 208–212.